Work

Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e16522

Authors: Renee Maria Saliby, Chris Labaki, Wanling Xie, Taylor Nonato, Andrew Lachlan Schmidt, Ziad Bakouny, Wenxin Xu, Praful Ravi, David A. Braun, Michelle S. Hirsch, Rana R. McKay, Toni K. Choueiri, Bradley Alexander McGregor

Institutions: Dana-Farber Cancer Institute, Moores Cancer Center, Cairns Hospital, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital, University of California San Diego

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286297400

Cites:

Cited by:

Related to: 10